uniQure (QURE) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" QURE shares.
View QURE analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 1-year target prices for uniQure's shares. Their QURE share price forecasts range from $14.00 to $57.00. On average, they anticipate the company's share price to reach $44.70 in the next twelve months. This suggests a possible upside of 554.5% from the stock's current price.
View analysts price targets for QURE or view top-rated stocks among Wall Street analysts.

uniQure's stock was trading at $22.67 at the beginning of the year. Since then, QURE stock has decreased by 69.9% and is now trading at $6.83.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our QURE earnings forecast.

uniQure (NASDAQ:QURE) posted its earnings results on Tuesday, August, 1st. The biotechnology company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of $2.97 by $4.41. The biotechnology company earned $2.42 million during the quarter, compared to the consensus estimate of $168.66 million. uniQure had a negative net margin of 166.83% and a negative trailing twelve-month return on equity of 44.91%.

Global X Genomics & Biotechnology ETF holds 154,612 shares of QURE stock, representing 1.46% of its portfolio.

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

uniQure trades on the NASDAQ under the ticker symbol "QURE."

uniQure's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.37%), State Street Corp (5.33%), 683 Capital Management LLC (2.71%), Caption Management LLC (0.00%), Goldman Sachs Group Inc. (0.91%) and Schonfeld Strategic Advisors LLC (0.90%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Paula Soteropoulos, Pierre Caloz, Rachelle Suzanne Jacques, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends.

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QURE stock can currently be purchased for approximately $6.83.

uniQure (NASDAQ:QURE) has a market capitalization of $325.79 million and generates $106.48 million in revenue each year. The biotechnology company earns $-126,790,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis.

The company employs 501 workers across the globe.

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272.